Abstract
The initiation of mRNA translation plays a pivotal role in gene expression and has profound implications for tumorigenesis, tumor progression, and drug resistance. The eIF4F complex, a critical component of the classical translation initiation mechanism, is widely exploited by tumor cells to enhance overall protein synthesis while selectively targeting the translation of oncogenes. Beyond eIF4F, other factors and pathways, such as mTOR, contribute significantly to malignancy. Dysregulated translation initiation enables tumor cells to thrive in challenging environments like hypoxia and facilitates the transformation of the tumor immune microenvironment, allowing cancer cells to evade immune detection. Furthermore, translation dysfunction contributes to drug resistance by increasing the production of proteins that support cell survival under therapeutic stress. This review examines the significance of translation initiation regulation in cancer and evaluates the potential for combination therapies targeting these pathways.
Introduction: The Translation Bottleneck
In the traditional "central dogma" of molecular biology, cancer research has historically focused on DNA mutations and mRNA transcription levels. However, protein levels in tumor cells frequently do not correlate with their mRNA counterparts. The primary "bottleneck" responsible for this discrepancy is translation initiation—the complex process of assembling a ribosome onto an mRNA strand to begin protein synthesis.
Tumor cells exploit this bottleneck to selectively produce oncogenic proteins that fuel growth, even under harsh conditions like hypoxia (low oxygen) or nutrient deprivation. By synthesizing findings from over 170 recent studies, this review explores how hijacked translation machinery drives malignancy and provides a "backdoor" for cells to survive modern treatments.
The eIF4F Complex: A Master Switch for Growth
The eIF4F complex, consisting of eIF4E, eIF4G, and eIF4A, acts as a critical regulator of protein synthesis. eIF4E, in particular, is often overexpressed in cancers, acting as a driver that prioritizes the translation of mRNAs involved in cell survival and proliferation. By controlling the rate-limiting step of translation, the eIF4F complex allows tumors to maintain a high metabolic rate and rapid cell division.
Adaptation via Non-Canonical Bypass Mechanisms
When tumors are under stress—whether from therapeutic intervention or environmental factors like low oxygen—they can switch from standard cap-dependent translation to alternative methods. These "non-canonical" pathways, such as Internal Ribosomal Entry Sites (IRES) or m6A-mediated initiation, allow cancer cells to keep producing essential survival proteins even when the "main power" of standard translation is cut. This plasticity is a hallmark of aggressive, adaptable tumors.
Reshaping the Tumor Microenvironment and Metabolism
Translation initiation is not merely an internal cellular process; it dictates how the tumor interacts with its surroundings. Dysregulated initiation facilitates metabolic reprogramming, fueling the rapid glycolysis and lipid synthesis required for growth. Furthermore, it mediates immune evasion by increasing the expression of proteins like PD-L1, which helps the tumor "hide" from T cells, effectively creating an immunosuppressive microenvironment.
Clinical Landscape and Therapy Resistance
The dysfunction of translation initiation is a major contributor to drug resistance. Overexpression or phosphorylation of factors like eIF4E and eIF2α directly aids resistance against common treatments, including Paclitaxel, Tamoxifen, and various immunotherapies.
Currently, mTOR inhibitors are the only class of translation-targeting drugs approved for clinical use, though they often face challenges with resistance. However, combination therapies show significant potential. For instance, early-phase trials combining Ribavirin and Ara-C showed a 23.80% Overall Response Rate (ORR) in patients with Acute Myeloid Leukemia (AML).
Future Directions: Precision Translatomics
A major challenge in targeting translation is the lack of specificity; many current inhibitors affect broad cellular processes, leading to side effects. The future of the field lies in developing "surgical" inhibitors for specific eIF subunits and identifying robust biomarkers to predict patient response.
The burgeoning field of "translatomics" (e.g., Ribo-seq) will be instrumental in this effort. By allowing researchers to see exactly which mRNAs are being translated in real-time, translatomics paves the way for a more personalized, precision medicine approach to treating cancer.
Summary updated